SEC Form 4															
FO	RM 4	UNITED	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549												
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).			Filed pursuar	t to Section 16(a) of tition 30(h) of the In	of the Securiti		ES	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5							
1. Name and Address of Reporting Person* Lang James Paul				er Name and Ticker nizeRx Corp		ymbol	(Chec	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner							
(Last)	(Last) (First) (Middle)			of Earliest Transac 2023	tion (Month/D	ay/Year)		Officer (give title Other (s below) below)							
C/O OPTIMIZERX CORPORATION 260 CHARLES STREET, SUITE 302				endment, Date of (Original Filed	(Month/Day/Ye	Line)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person							
(Street) WALTHAM MA 02453		02453							Form filed by More than One Reporting Person						
(City)	(State)	(Zip)		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.											
		Table I - Nor	n-Derivative S	ecurities Acq	uired, Disp	posed of, c	or Ben	eficially	Owned						
Da			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Disposed Of 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership				
					Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)				

Common Stock				5/07/20	7/2023		М	4,637	A	\$0 ⁽¹⁾	44,	697	D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Restricted Stock Units	(1)	06/07/2023		М			4,637	(2)	(2)	Common Stock	4,637	\$0	0	D	
Restricted Stock Units	(3)	06/07/2023		A		10,061		(4)	(4)	Common Stock	10,061	\$0	10,061	D	

Explanation of Responses:

1. Restricted stock units convert into common stock on a one-for-one basis.

The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person.

> /s/ Marion Odence-Ford, by Power of Attorney

08/17/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

2. On June 7, 2022 the reporting person was granted 4,637 restricted stock units which vested in full on June 7, 2023.

3. Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock.

4. The restricted stock units will vest in full on the earlier of the first anniversary of the date of grant or the date of the Company's next annual meeting of shareholders.

Remarks: